814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade

• Akseli Hemminki,
• Víctor Cervera-Carrascón,
• Riikka Havunen,
• Otto Hemminki,
• Anna Kanerva,
• João Manuel Santos,
• Camilla Heiniö,
• Jari Räsänen,
• Suvi Sorsa,
• Santeri A Pakola,
• James Clubb,
• Tatiana V Kudling,
• Susanna AM Grönberg-Vähä-Koskela,
• Victor Arias,
• Dafne Alves Quixabeira,
• Iris Lähdeniemi,
• Eva Sutinen,
• Kristian Borenius,
• Mikko Mäyränpää,
• Eero Altonen,
• Emmy W Verschuren,
• Ilkka Ilonen

Affiliations

Akseli Hemminki

3TILT Biotherapeutics, Helsinki, Finland

Víctor Cervera-Carrascón

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Riikka Havunen

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Otto Hemminki

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Anna Kanerva

5Department of Gynecology and Obstetrics, Helsinki University Hospital, Helsinki, Finland

João Manuel Santos

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Camilla Heiniö

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Jari Räsänen

8General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital and Faculty of Medicine, University of Helsinki, Helsinki, Finland

Suvi Sorsa

1Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Santeri A Pakola

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

James Clubb

2TILT Biotherapeutics Ltd., Helsinki, Finland

Tatiana V Kudling

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Susanna AM Grönberg-Vähä-Koskela

4Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland

Victor Arias

2Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

Dafne Alves Quixabeira

2TILT Biotherapeutics Ltd., Helsinki, Finland

Iris Lähdeniemi

3Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

Eva Sutinen

4iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland

Kristian Borenius

4iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland

Mikko Mäyränpää

9Pathology, University of Helsinki and Helsinki University Hospital (HUSLAB), Helsinki, Finland

Eero Altonen

10Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

Emmy W Verschuren

3Translational Lung Cancer Research Group, Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland

Ilkka Ilonen

4iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland